Skye Bioscience, Inc. — Director's Dealing 2015

Jun 2, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nemus Bioscience, Inc. (NMUS)
CIK: 0001516551
Period of Report: 2015-05-29

Reporting Person: McLaughlin Gerald W. (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-05-29	Series A Preferred Stock	$2.50	P	10000	Acquired		Common Stock (10000)	Direct
2015-05-29	Common Stock Warrant (Right to Buy)	$5.00	P	2000	Acquired	2020-05-29	Common Stock (2000)	Direct

Footnotes

F1: The Series A Convertible Preferred Stock are automatically convertible in accordance with the Issuer's Certificate of Designation and Certificate of Correction, which are included as exhibit 3.1 and 3.2, respectively, to the Issuer's Form 8-K filed on April 7, 2015, and do not have an expiration date.

F2: Pursuant to a Securities Purchase Agreement dated April 29, 2015, between the Reporting Person and the Issuer, the Reporting Person acquired 10,000 shares of Series A Preferred Stock and warrants to purchase an aggregate 2,000 shares of the Issuer's common stock at an exercise price of $5.00 per share in exchange for $25,000, or $2.50 per share.

F3: Subject to adjustment as specified in the Issuer's Certificate of Designation, which is included as exhibit 3.1 to the Issuer's Form 8-K filed on April 7, 2015.